UK markets closed

Galapagos NV (GLPGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
59.500.00 (0.00%)
At close: 11:44AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close59.50
Open51.00
Bid0.00 x 0
Ask0.00 x 0
Day's range59.50 - 59.50
52-week range51.00 - 195.50
Volume1,000
Avg. volume6,061
Market cap3.267B
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-4.48
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Here's Why Galapagos Stock Is Falling Today
    Motley Fool

    Here's Why Galapagos Stock Is Falling Today

    Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday. Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors.

  • Galapagos (GLPG) Falls on Inflammatory Study Data Readout
    Zacks

    Galapagos (GLPG) Falls on Inflammatory Study Data Readout

    Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

  • Globe Newswire

    Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Generally safe and well toleratedPositive efficacy signal in psoriasis patients at Week 440% of patients showed improvement of at least 50% in PASI response (PASI 50) with high dose of GLPG3667 at Week 4Data support initiation of Phase 2b dose finding study in psoriasis Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patient